Investigating how And-1 affects resistance to breast cancer treatment
The role of And-1 in R-loop and endocrine resistance in breast cancer
['FUNDING_R01'] · GEORGE WASHINGTON UNIVERSITY · NIH-11044612
This study is looking at a protein called And-1 to see how it affects the way some breast cancer patients stop responding to a common treatment, and it hopes to find new ways to help those patients by testing new drugs that target And-1.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | GEORGE WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (WASHINGTON, UNITED STATES) |
| Trial ID | NIH-11044612 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of a protein called And-1 in the development of resistance to aromatase inhibitors, a common treatment for estrogen receptor-positive breast cancer. The study aims to explore how And-1 influences the resolution of R-loops, which are structures that can disrupt gene expression. By utilizing both laboratory experiments and patient-derived models, the researchers will test new inhibitors targeting And-1 to potentially overcome treatment resistance in patients. This approach could lead to more effective therapies for those who have developed resistance to current treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are breast cancer patients with estrogen receptor-positive tumors who have developed resistance to aromatase inhibitors.
Not a fit: Patients with breast cancer who have not been treated with aromatase inhibitors or those with other types of breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new treatment options for breast cancer patients who have become resistant to aromatase inhibitors.
How similar studies have performed: Previous studies have shown promise in targeting similar mechanisms in cancer therapy, indicating potential for success with this novel approach.
Where this research is happening
WASHINGTON, UNITED STATES
- GEORGE WASHINGTON UNIVERSITY — WASHINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZHU, WENGE — GEORGE WASHINGTON UNIVERSITY
- Study coordinator: ZHU, WENGE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy, Breast Cancer, Breast Cancer Cell, Breast Cancer Model, Breast Cancer Patient